TAK

Takeda Pharmaceutical Company Limited $20.15 as of 2026-10-28
Model view — historical tendencies for the days ahead, not a forecast
Next 1 day
+0.0%
Next 1 week
+0.1%
Next 1 month
-0.3%
Seasonality
Weak window historically
Next 30 days (to Nov 28): -1.7% median, 40% of the last 15 years finished up.
20-year seasonality chart →
Mean reversion
Neutral — RSI(2) at 28
RSI(2) under 15 is oversold (this name has historically bounced); over 85 is overbought. Its dip-buy edge in history is +0.01%/day.
Mean-reversion stats →
1-month breakdown — Market · β 0.12 +0.3% · Seasonal tilt -0.7%
$63.6B market cap (#299 US) $54M/day volume 21% volatility +42% 1-year -36% from ATH
52-week range · 95% of the way up · -2% from the high
$12.99$20.55

Congressional trades in TAK Full tracker →

4 members · 3 buys / 4 sells · $63K–$245K disclosed · latest filing Sep 5, 2023.

SELL VF Virginia Foxx · traded Aug 29, 2023 $15K–$50K
SELL DG Daniel Goldman · traded Jul 10, 2023 $15K–$50K
BUY VF Virginia Foxx · traded Feb 16, 2023 $1K–$15K
BUY VF Virginia Foxx · traded Nov 1, 2022 $1K–$15K
SELL GG Greg Gianforte · traded Sep 11, 2019 $1K–$15K
SELL NT Nicholas Van Taylor · traded Mar 25, 2019 $15K–$50K
BUY GG Greg Gianforte · traded Dec 21, 2018 $15K–$50K

Earnings Full history →

Next report 2026-10-29 (Thursday, before open, in 0 days).

1-day std dev
1.5%
Finished up
56%
Biggest pop
+2.1%
Biggest drop
-2.5%

Standard deviation of the close-to-close move over the last 9 reports. History, not a forecast.

ReportedEst.Actual SurpriseGap Day 1Day 5
2023-07-27 beat 18.62 28.76 +54.4% +1.0% +1.0% -1.9%
2022-10-27 miss 67.54 20.03 -70.3% +1.0% +0.5% +1.1%
2022-07-28 miss 59.27 33.97 -42.7% -0.1% +0.8% -5.2%
2021-10-28 miss 97.00 -5.13 -105.3% +2.0% +2.1% +4.2%
2021-07-30 miss 95.00 64.00 -32.6% -0.6% -2.5% -3.7%
2021-05-11 miss 88.00 63.08 -28.3% -0.7% -1.5% +1.7%
2021-02-04 miss 105.00 29.78 -71.6% +0.9% -1.3% +0.6%
2020-10-29 miss 103.00 1.38 -98.7% +3.1% -0.9% +4.8%
2020-07-31 miss 85.00 26.35 -69.0% +1.6% +0.2% -0.1%

Not investment advice.